zuranolone
Adjunctive therapy • Brands: Zurzuvae
Last reviewed: 2026-02-12
General information
- Class: Adjunctive therapy
- Common US brands: Zurzuvae
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-12
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Neuroactive steroid and GABA-A receptor positive allosteric modulator. FDA-approved as a 14-day oral treatment course for postpartum depression (label).
Metabolism & Half‑life
- Metabolism: CYP3A4
- Half‑life: Single-dose range 19.7–24.6 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- ZURZUVAE (zuranolone) capsules prescribing information — DailyMed (2026)
- Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial — JAMA Psychiatry (2021)
- Zuranolone for the Treatment of Postpartum Depression — The American Journal of Psychiatry (2023)
- Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development — CNS Drugs (2019)